How to buy Rigel Pharmaceuticals stock | $3.72

Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around 0.00.

Rigel Pharmaceuticals stock price (NASDAQ: RIGL)

Use our graph to track the performance of RIGL stocks over time.

Rigel Pharmaceuticals shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$3.72
52-week range	$2.14 - $5.50
50-day moving average	$4.24
200-day moving average	$3.93
Wall St. target price	$8.50
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-0.35

Buy Rigel Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Rigel Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Rigel Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Rigel Pharmaceuticals price performance over time

Historical closes compared with the close of $3.72 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	-15.65%
3 months (2021-04-30)	3.72
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Rigel Pharmaceuticals financials

Revenue TTM	$133.9 million
Gross profit TTM	$47.6 million
Return on assets TTM	-2.87%
Return on equity TTM	-14.65%
Profit margin	-8.58%
Book value	$0.46
Market capitalisation	$696 million

TTM: trailing 12 months

Shorting Rigel Pharmaceuticals shares

There are currently 20.8 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 3.6% down from 21.6 million last month.

There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.

Rigel Pharmaceuticals's "short interest ratio" (SIR)

Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 1.7 million). Rigel Pharmaceuticals's SIR currently stands at 12.58. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 12580 shares are currently held short.

However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1228% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 123 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rigel Pharmaceuticals.

Find out more about how you can short Rigel Pharmaceuticals stock.

Rigel Pharmaceuticals share dividends

We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.

Have Rigel Pharmaceuticals's shares ever split?

Rigel Pharmaceuticals's shares were split on a 1:9 basis on 24 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.

Rigel Pharmaceuticals share price volatility

Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $2.14 up to $5.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.506. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Rigel Pharmaceuticals overview

Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co. , Ltd.

Frequently asked questions

What percentage of Rigel Pharmaceuticals is owned by insiders or institutions?
Currently 0.214% of Rigel Pharmaceuticals shares are held by insiders and 89.005% by institutions. How many people work for Rigel Pharmaceuticals?
Latest data suggests 169 work at Rigel Pharmaceuticals. When does the fiscal year end for Rigel Pharmaceuticals?
Rigel Pharmaceuticals's fiscal year ends in December. Where is Rigel Pharmaceuticals based?
Rigel Pharmaceuticals's address is: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080 What is Rigel Pharmaceuticals's ISIN number?
Rigel Pharmaceuticals's international securities identification number is: US7665596034 What is Rigel Pharmaceuticals's CUSIP number?
Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108